Wednesday, October 14, 2026
Via News Knowledge File

AT&T Inc.

organization80% conf.·synced Aug 13, 2026

Telecommunications company providing wireless, fiber, and broadband services

52
sourced metrics
242
relationships
20
stated objectives
1
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Pe Ratio
8ratio
Jul 24, 2026source
52 Week High
29.79USD
Jul 24, 2026source
Stock Price
24.13USD
Jul 24, 2026source
Internet Customers Added
646000customers
Jul 22, 2026source
Eps
0.65USD_per_share
Jul 22, 2026source
Shares Outstanding
6.9billions
Jul 22, 2026source
Diluted Eps Continuing Ops
0.66USD_per_share
Jul 22, 2026source
Annual Dividend Per Share
1.11USD
Jul 22, 2026source
Fixed Wireless Customers Added
279000customers
Jul 22, 2026source
Adjusted Ebitda Margin
39.1percent
Jul 22, 2026source
Planned Shareholder Returns Total
18USD
Jul 22, 2026source
Annual Dividend Total
7.6USD
Jul 22, 2026source
Free Cash Flow
4.7USD
Jul 22, 2026source
Fiber Locations Passed
38.6millions
Jul 22, 2026source
Fiber Customers Added
367000customers
Jul 22, 2026source
Debt
173.99USD
May 20, 2026source
Fiber Passings Target
4000000millions
May 20, 2026source
Capex Commitment
19USD
May 20, 2026source

Stated objectives

Adjusted EPS 3-year CAGR target through 2028

source
target: double-digit by 2028-01-01 00:00:00stated

Free cash flow target for 2026

source
target: $18B+ by 2026-01-01 00:00:00stated

Adjusted EBITDA growth target for 2026

source
target: 3-4% by 2026-01-01 00:00:00stated

Share repurchase target for 2026

source
target: $8B by 2026-01-01 00:00:00stated

Adjusted EBITDA annual growth target by 2028

source
target: 5%+ by 2028-01-01 00:00:00stated

Free cash flow growth target for 2027

source
target: +$1B by 2027-01-01 00:00:00stated

Free cash flow growth target for 2028

source
target: +$2B by 2028-01-01 00:00:00stated

Annual cost savings target by 2028

source
target: $4B+ by 2028-01-01 00:00:00stated

Total shareholder returns target for 2026-2028

source
target: $45B+ (30% of market cap, 75%+ of expected FCF) by 2028-01-01 00:00:00stated

Net debt to EBITDA ratio target after acquisitions close

source
target: ~3.2x immediately, ~3.0x by year-end 2026, return to 2.5x ra by 2029-01-01 00:00:00stated

Relationship graph · 242 connections

Competes with
62
Covered by
25
Customer of
19
Supplies to
18
acquired by
17
Employs
11
Developed by
10
Built on
9

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com